Eli Lilly and Company (LLY) Names Melissa Barnes Chief Ethics and Compliance Officer and Senior Vice President; Announces Retirement of Anne Nobles
10/30/2012 10:07:52 AM
INDIANAPOLIS, Oct. 30, 2012 -- Eli Lilly and Company (NYSE: LLY) today announced that Melissa Barnes will be promoted to chief ethics and compliance officer and senior vice president of enterprise risk management effective Jan. 1, 2013. Barnes will replace Anne Nobles, who will retire at the end of the year.
Barnes, vice president and deputy general counsel, is currently responsible for litigation, compliance and specialty legal areas, including regulatory and human resources. In her new role, Barnes will report to John Lechleiter, Ph.D., chairman, president and CEO, and will serve on the company's executive committee.
"Melissa's legal background and extensive experience at Lilly make her the right person to assume this important role within our company," said Lechleiter. "Lilly is committed to conducting our business with the highest level of integrity and in full compliance with the laws and regulations that govern our operations. Having someone with Melissa's qualifications lead our ethics and compliance organization is evidence of this commitment."
Barnes is a graduate of Harvard Law School. She joined the company in 1994 and has served in a number of legal and business positions at Lilly, specializing in legal work related to compliance, litigation, human resources, regulatory, business management strategy, and global marketing and sales.
Nobles joined Lilly in 1990 and has served in various leadership positions, including vice president of corporate affairs. She became Lilly's chief compliance officer in 2007 and has served on the company's executive committee since 2009.
"Anne has provided critical leadership at a very important time for our company," said Lechleiter. "Her contributions have been instrumental in building a comprehensive company-wide ethics and compliance program. She has worked closely with Lilly business leaders to ensure that compliance is effectively integrated into our business plans and our day-to-day activities."
About Eli Lilly and Company
Lilly, a leading innovation-driven corporation, is developing a growing portfolio of pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations. Headquartered in Indianapolis, Ind., Lilly provides answers - through medicines and information - for some of the world's most urgent medical needs. Additional information about Lilly is available at www.lilly.com. C-LLY